Cadila Healthcare Soars Over 4% Receives 1st Product Approval For Moraiya Plant Post USFDA Audit

Cadila Healthcare soared over 4% on the bourses in the opening hours of Friday’s trade.

The pharma major has received final approval from the USFDA to market Levofloxacin Injection, 500 mg/20mL and 750 mg/30mL. Levofloxacin is used in the treatment of bacterial infections and will be produced at the group's formulations manufacturing plant at Moraiya, Ahmedabad.

With this approval, it marks the beginning of the approval process for filings made from the Moraiya manufacturing plant after successfully completing the USFDA audit from February with Zero 483 observations.

The group now has more than 115 approvals and so far filed over 300 ANDA’s since the commencement of the filing process in FY 2003-04.

Meanwhile, BSE Healthcare index gained over 148 points or 1.08% at 13870.92 levels on the first half of today’s intraday trade.

For Quick Trial – 8962000225 ✔ 
or mail us here:
or visit
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔
Share on Google Plus Share on Pinterest

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.